Trial · NCT00822692

Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection

NCT00822692, Not applicable, Completed, 59th Medical Wing; results first posted 2009-09-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection. Trials, record NCT00822692. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00822692

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
NCT number: NCT00822692
Status: Completed
Phases: Not applicable
Enrollment: 139 participants, actual
Lead sponsor: 59th Medical Wing
Conditions: Abscess, Methicillin-Resistant Staphylococcus Aureus Infection
Interventions: Trim/ Sulfa DS, placebo
First posted: 2009-01-14
Last updated: 2015-12-21
Results first posted: 2009-09-03

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Recurrence Rates of Abscesses	30 days after incision and drainage	Number of patient with a new abscess in same or different location as previous lesion

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Recurrence Rates of Abscesses	30 days after incision and drainage		participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Recurrence Rates of Abscesses	Bactrim DS (800/160) Two Tablets PO BID x 7 Days		4		participants
Recurrence Rates of Abscesses	Matched Placebo 2 Pills PO BID x 7 Days		14		participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Bactrim DS (800/160) Two Tablets PO BID x 7 Days	63
Overall Study	STARTED	Matched Placebo 2 Pills PO BID x 7 Days	76
Overall Study	COMPLETED	Bactrim DS (800/160) Two Tablets PO BID x 7 Days	46
Overall Study	COMPLETED	Matched Placebo 2 Pills PO BID x 7 Days	51
Overall Study	NOT COMPLETED	Bactrim DS (800/160) Two Tablets PO BID x 7 Days	17
Overall Study	NOT COMPLETED	Matched Placebo 2 Pills PO BID x 7 Days	25

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	treatment failure	Skin and subcutaneous tissue disorders	Bactrim DS (800/160) Two Tablets PO BID x 7 Days	15	63
other	treatment failure	Skin and subcutaneous tissue disorders	Matched Placebo 2 Pills PO BID x 7 Days	27	76

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Bactrim DS (800/160) Two Tablets PO BID x 7 Days
Total, all-cause mortality	Matched Placebo 2 Pills PO BID x 7 Days
Total, other adverse events	Bactrim DS (800/160) Two Tablets PO BID x 7 Days	15	63
Total, other adverse events	Matched Placebo 2 Pills PO BID x 7 Days	27	76
Total, serious adverse events	Bactrim DS (800/160) Two Tablets PO BID x 7 Days	0	63
Total, serious adverse events	Matched Placebo 2 Pills PO BID x 7 Days	0	76

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
20346539	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Bactrim DS (800/160) Two Tablets PO BID x 7 Days vs Matched Placebo 2 Pills PO BID x 7 Days: Recurrence Rates of Abscesses	Trial comparisons
Bactrim DS (800/160) Two Tablets PO BID x 7 Days vs Matched Placebo 2 Pills PO BID x 7 Days: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00822692

GET https://conductscience.org/api/trials/v1/NCT00822692/registered

API reference For AI assistants